Perseus Proteomics Inc. (TYO:4882)
155.00
-6.00 (-3.73%)
May 29, 2026, 3:30 PM JST
Perseus Proteomics Revenue
In the fiscal year ending March 31, 2026, Perseus Proteomics had annual revenue of 135.00M JPY with 12.50% growth. Perseus Proteomics had revenue of 31.90M in the quarter ending March 31, 2026, a decrease of -13.63%.
Revenue
135.00M
Revenue Growth
+12.50%
P/S Ratio
17.28
Revenue / Employee
4.22M
Employees
32
Market Cap
2.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 135.00M | 15.00M | 12.50% |
| Mar 31, 2025 | 120.00M | 20.00M | 20.00% |
| Mar 31, 2024 | 100.00M | 6.00M | 6.38% |
| Mar 31, 2023 | 94.00M | 23.00M | 32.39% |
| Mar 31, 2022 | 71.00M | 4.00M | 5.97% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.52T |
| Astellas Pharma | 2.14T |
| Daiichi Sankyo Company | 2.12T |
| Chugai Pharmaceutical | 1.29T |
| Ono Pharmaceutical | 515.79B |
| Kyowa Kirin | 510.57B |
| Santen Pharmaceutical | 291.62B |
| JCR Pharmaceuticals | 40.32B |